PMC:7318948 / 8942-9202 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T120","span":{"begin":52,"end":64},"obj":"CHEBI:63611;CHEBI:63611"},{"id":"T121","span":{"begin":78,"end":83},"obj":"SP_6;NCBITaxon:9606"},{"id":"T122","span":{"begin":84,"end":100},"obj":"PR:000024938"},{"id":"T123","span":{"begin":102,"end":120},"obj":"DG_36"},{"id":"T124","span":{"begin":122,"end":127},"obj":"SP_6;NCBITaxon:9606"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T51","span":{"begin":4,"end":10},"obj":"Body_part"},{"id":"T52","span":{"begin":201,"end":212},"obj":"Body_part"}],"attributes":[{"id":"A51","pred":"fma_id","subj":"T51","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A52","pred":"fma_id","subj":"T52","obj":"http://purl.org/sig/ont/fma/fma9608"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T32","span":{"begin":4,"end":10},"obj":"Body_part"},{"id":"T33","span":{"begin":201,"end":212},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"uberon_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A33","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0002371"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T51","span":{"begin":28,"end":31},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0018942"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T108","span":{"begin":4,"end":10},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T109","span":{"begin":4,"end":10},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T110","span":{"begin":4,"end":10},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T111","span":{"begin":78,"end":83},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T112","span":{"begin":122,"end":127},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T113","span":{"begin":201,"end":205},"obj":"http://purl.obolibrary.org/obo/UBERON_0002481"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T68","span":{"begin":17,"end":27},"obj":"Chemical"},{"id":"T69","span":{"begin":28,"end":31},"obj":"Chemical"},{"id":"T70","span":{"begin":32,"end":43},"obj":"Chemical"},{"id":"T71","span":{"begin":52,"end":64},"obj":"Chemical"},{"id":"T72","span":{"begin":84,"end":94},"obj":"Chemical"},{"id":"T73","span":{"begin":95,"end":100},"obj":"Chemical"},{"id":"T74","span":{"begin":102,"end":120},"obj":"Chemical"}],"attributes":[{"id":"A68","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_61049"},{"id":"A69","pred":"chebi_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/CHEBI_8764"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A71","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_63611"},{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A73","pred":"chebi_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A74","pred":"chebi_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}

{"project":"LitCovid-PubTator","denotations":[{"id":"200","span":{"begin":78,"end":83},"obj":"Species"},{"id":"201","span":{"begin":122,"end":127},"obj":"Species"}],"attributes":[{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"Tax:9606"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T96","span":{"begin":0,"end":260},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"48M Kidney, 2003 Tacrolimus MMF Oseltamivir, abidol moxifloxacin, recombinant human interferon alpha, methylprednisolone, human IVIG TacrolimusMMF discontinued Not Reported 2.49 64% 31.25 Not Reported Bone marrow suppression due to MMFFull recovery 42 days [4]"}